Next-Generation Bispecific Nanobody for CD3 Complex and TACSTD2 Engagement in Pancreas Cancer

VHH-P341 is a novel humanized bispecific nanobody designed to simultaneously target CD3 Complex (T Cell Receptor Complex) and tumor associated calcium signal transducer 2 (TACSTD2). Currently in the Biological Testing stage, VHH-P341 leverages the unique antigen recognition capabilities of single-domain antibodies to engage cytotoxic T cells via CD3 Complex, while specifically directing them to TACSTD2-expressing tumors. Through this dual targeting approach, VHH-P341 shows strong potential in the therapeutic management of pancreas cancer, where innovative immunological strategies are urgently needed. The program is developed for further advancement towards clinical application in patients with difficult-to-treat malignancies such as pancreas cancer.

Licensing Opportunity

VHH-P341 is available for out-licensing and collaboration. We welcome industry partners interested in advancing this innovative bispecific nanobody platform into clinical development for pancreas cancer. Please contact us to discuss potential partnership opportunities.

Development Phase

Modality

VHH-P341 is a bispecific antibody composed of a humanized single-domain antibody (nanobody) targeting TACSTD2, fused to an anti-CD3 single-chain variable fragment via a flexible GGGGSGGGS linker, and produced in human embryonic kidney cells. As a single-domain antibody, the nanobody component of VHH-P341 confers a smaller molecular size and improved tissue penetration, offering clear advantages in reaching tumor cells within the dense stroma of pancreatic tumors. The high stability and solubility of nanobodies further enhance therapeutic viability. Bispecificity enables VHH-P341 to act as an immune cell engager, efficiently redirecting T cells toward TACSTD2-positive cancer cells for targeted cytotoxicity. This structural design is particularly advantageous in the immunologically challenging microenvironment of pancreas cancer.

Target

CD3 Complex and TACSTD2 are well-established molecular targets with critical roles in immune regulation and oncogenesis. CD3 Complex, a multi-subunit protein complex, is predominantly found on the surface of T lymphocytes and is essential for T cell activation and signal transduction. TACSTD2, also known as an epithelial cell surface antigen, is frequently overexpressed in various epithelial cancers, including pancreas cancer, and is implicated in cell adhesion, proliferation, and metastasis. CD3 Complex enables T cell redirection for targeted cancer immunotherapy, while TACSTD2 acts as a tumor-associated antigen, marking malignant cells for immune-mediated elimination. The dual-targeting approach of VHH-P341 positions it strategically for both activating immune effector cells via CD3 Complex and enabling precise tumor targeting through TACSTD2, offering significant translational value in immuno-oncology.

Mechanism of Action

VHH-P341 functions as a T cell engager by binding simultaneously to CD3 Complex on T cells and TACSTD2 expressed on tumor cells. This dual interaction promotes the formation of a cytolytic synapse, allowing for the targeted activation of T cells in close proximity to TACSTD2-positive malignancies. Upon binding, VHH-P341 facilitates T cell–mediated cytotoxicity through immune synapse formation, leading to selective tumor cell apoptosis. The nanobody platform enables modularity, supporting further innovations such as bispecifics, antibody–drug conjugates, or multispecific therapeutics. By harnessing endogenous immune mechanisms through CD3 Complex and addressing tumor specificity with TACSTD2, VHH-P341 exemplifies the next frontier in targeted, immune-mediated cancer therapy.

Pancreas Cancer

Pancreas cancer is a highly lethal malignancy characterized by late diagnosis, rapid progression, and limited responsiveness to conventional therapies. Worldwide, pancreas cancer ranks among the leading causes of cancer-related mortality, with increasing incidence and a generally poor prognosis due to the lack of early symptoms and effective screening strategies. Standard treatment modalities involve surgery, chemotherapy, and radiation, with a recent expansion into targeted and immunotherapy approaches. However, therapeutic outcomes remain hampered by dense tumor stroma, low immunogenicity, early metastasis, and pronounced therapeutic resistance. There is a critical unmet need for treatments capable of overcoming the immunosuppressive tumor microenvironment and improving long-term survival. VHH-P341, by combining potent T cell activation via CD3 Complex with precise tumor targeting through TACSTD2, offers a promising new direction for effective and selective immunotherapy in pancreas cancer, addressing major gaps in current treatment paradigms.